drugset / Trial / NCT05668936

A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

NCT05668936

Phase 1 Terminated 31 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.

Timeline

Start
2023-01-03
Primary completion
2023-03-10
Completion
2023-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cotadutide Peptide Subcutaneous
Subject Moxifloxacin Small molecule Oral